ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 582

Baseline Power Doppler and Multi-Biomarker Disease Activity Score Predict 12-Week Disease Activity Response to Tofacitinib

Amir Razmjou1, Jenny Brook2, Gurjit Kaeley3, David Elashoff2 and Veena K. Ranganath4, 1Internal Medicine, UCLA-David Geffen School of Medicine, Los Angeles, CA, 2Department of Medicine Statistics Core, UCLA David Geffen School of Medicine, Los Angeles, CA, 3UF Health Jacksonville, Jacksonville, FL, 41000 VETERAN BLVD., RM 32-59, UCLA, Los Angeles, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA), tofacitinib and ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Point of care tailored treatment strategies are of value to improve rheumatoid arthritis (RA) patient outcomes. Musculoskeletal ultrasound (MSUS) is increasingly used as a modality by which rheumatologists diagnose and monitor the progression of RA. The multi-biomarker disease activity (MBDA) blood test is a commercially available assay that measures twelve inflammatory biomarkers to score RA disease activity on a scale of 1-100. This pilot study evaluated whether baseline MSUS and MBDA scores or their early changes, are predictive of 12-week clinical response in RA patients treated with tofacitinib.

Methods: 25 RA patients who met entry criteria (including baseline disease activity score using ESR [DAS28] >3.2 and power Doppler US [PDUS] score >10) were treated with open-label tofacitinib at the approved dose of 5 mg PO BID and assessed at baseline, 2 weeks and 12 weeks. MSUS was performed at each visit scoring 34-joints for PDUS and GSUS. Other metrics examined were MBDA score, clinical disease activity index (CDAI), disease activity score (DAS28). Associations between MBDA score/PDUS/GSUS at baseline or their changes from baseline to 2 or 12 weeks, and the change in DAS28/CDAI from baseline to 12 weeks, were assessed using Pearson correlation coefficients.

Results: Mean age was 52 years, mean disease duration 10.4 years, 88% of patients were female, 40% Caucasian, and 96% were RF/CCP positive. At baseline, the mean (SD) DAS28 was 6.26 (1.2) and CDAI was 40 (13.2). There was significant improvement in PDUS, GSUS, MBDA score, DAS28, and CDAI over 12 weeks (all p<0.0001). Correlations of 12-week changes in MBDA score or MSUS with 12-week changes in CDAI or DAS28 were all significant (correlation coefficients 0.44-0.58), except for GSUS with DAS28 (Table 1). Changes from baseline to 2 weeks in PDUS or GSUS were associated with significant DAS28 response at 12 weeks (Table 1). Baseline PDUS, GSUS and MBDA score were significant predictors of 12-week CDAI or DAS28 responses, except for GSUS with DAS28 response (Table 1).

Conclusion: This study showed that RA patients treated with tofacitinib for 12 weeks demonstrated significant responses with clinical, imaging, and biomarker end-points. In addition, baseline PDUS and MBDA score were predictive of the DAS28 and CDAI response at 12 weeks. This is the first study to evaluate early MSUS and MBDA changes as predictors of clinical response in RA patients treated with tofacitinib.


Disclosure: A. Razmjou, None; J. Brook, None; G. Kaeley, None; D. Elashoff, Genentech, Inc., 2,Pfizer, Inc., 2,mallinkrodt, 2,Amgen Inc., 5; V. K. Ranganath, Genentech, Inc., 2,Pfizer, Inc., 2,mallinkrodt, 2,Amgen Inc., 5.

To cite this abstract in AMA style:

Razmjou A, Brook J, Kaeley G, Elashoff D, Ranganath VK. Baseline Power Doppler and Multi-Biomarker Disease Activity Score Predict 12-Week Disease Activity Response to Tofacitinib [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/baseline-power-doppler-and-multi-biomarker-disease-activity-score-predict-12-week-disease-activity-response-to-tofacitinib/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-power-doppler-and-multi-biomarker-disease-activity-score-predict-12-week-disease-activity-response-to-tofacitinib/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology